Pfizer reportedly aims to market OTC Lipitor after patent expiration

Pfizer is considering launching a nonprescription form of blockbuster cholesterol-lowering drug Lipitor after a key patent expires in November, sources said. However, Pfizer is expected to have trouble doing so because of the FDA's concern that patients will misuse statins without medical guidance. "We can confirm that we have strategic plans in place for Lipitor's loss of exclusivity and will comment no further at this time," said Pfizer spokesman Raymond Kerins.

View Full Article in:

New York Times (tiered subscription model), The · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA